Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 223

1.

Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation?

Piano S, Morando F, Fasolato S, Cavallin M, Boscato N, Boccagni P, Zanus G, Cillo U, Gatta A, Angeli P.

J Hepatol. 2011 Aug;55(2):491-6. doi: 10.1016/j.jhep.2011.02.002. Epub 2011 Feb 18.

2.

Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.

Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, Soriano G, Terra C, Fábrega E, Arroyo V, Rodés J, Ginès P; TAHRS Investigators.

Gastroenterology. 2008 May;134(5):1352-9. doi: 10.1053/j.gastro.2008.02.024. Epub 2008 Feb 14.

PMID:
18471512
3.

Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation.

Caraceni P, Santi L, Mirici F, Montanari G, Bevilacqua V, Pinna AD, Bernardi M.

Dig Liver Dis. 2011 Mar;43(3):242-5. doi: 10.1016/j.dld.2010.08.001. Epub 2010 Sep 15.

PMID:
20833118
4.

Terlipressin in hepatorenal syndrome: Evidence for present indications.

Rajekar H, Chawla Y.

J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:109-14. doi: 10.1111/j.1440-1746.2010.06583.x. Review.

PMID:
21199521
5.

Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice.

Angeli P, Gines P.

J Hepatol. 2012 Nov;57(5):1135-40. doi: 10.1016/j.jhep.2012.06.024. Epub 2012 Jun 26. Review.

6.

Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.

Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O'Leary JG, Ganger D, Jamil K, Pappas SC; REVERSE Study Investigators.

Gastroenterology. 2016 Jun;150(7):1579-1589.e2. doi: 10.1053/j.gastro.2016.02.026. Epub 2016 Feb 16.

PMID:
26896734
7.

Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.

Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jiménez W, Arroyo V, Rodés J.

Hepatology. 2002 Oct;36(4 Pt 1):941-8.

PMID:
12297842
8.

Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study.

Alessandria C, Debernardi-Venon W, Carello M, Ceretto S, Rizzetto M, Marzano A.

Dig Liver Dis. 2009 Apr;41(4):298-302. doi: 10.1016/j.dld.2008.09.014. Epub 2009 Jan 20.

PMID:
19158001
9.

Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome.

Testro AG, Wongseelashote S, Angus PW, Gow PJ.

J Gastroenterol Hepatol. 2008 Oct;23(10):1535-40. Epub 2008 Sep 3.

PMID:
17784863
10.

Terlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study.

von Kalckreuth V, Glowa F, Geibler M, Lohse AW, Denzer UW.

Z Gastroenterol. 2009 Jan;47(1):21-6. doi: 10.1055/s-0028-1109084. Epub 2009 Jan 20.

PMID:
19156588
11.

Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation.

Ganne-Carrié N, Hadengue A, Mathurin P, Durand F, Erlinger S, Benhamou JP.

Dig Dis Sci. 1996 Jun;41(6):1054-6.

PMID:
8654133
12.

Hepatorenal syndrome.

Angeli P, Morando F, Cavallin M, Piano S.

Contrib Nephrol. 2011;174:46-55. doi: 10.1159/000329235. Epub 2011 Sep 9. Review.

PMID:
21921608
13.

Terlipressin and albumin combination treatment in hepatorenal syndrome.

Danalioglu A, Cakaloglu Y, Karaca C, Aksoy N, Akyuz F, Ozdil S, Demir K, Besisik F, Boztas G, Mungan Z, Kaymakoglu S, Okten A.

Hepatogastroenterology. 2003 Dec;50 Suppl 2:ccciii-cccv.

PMID:
15244209
14.

Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2.

Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M.

Eur J Gastroenterol Hepatol. 2002 Dec;14(12):1363-8.

PMID:
12468959
15.

Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study.

Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, Demontis R, Henry-Biabaud E, Fievet P, Opolon P, Poynard T, Cadranel JF.

Eur J Gastroenterol Hepatol. 2002 Feb;14(2):153-8.

PMID:
11981339
16.

Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.

Sagi SV, Mittal S, Kasturi KS, Sood GK.

J Gastroenterol Hepatol. 2010 May;25(5):880-5. doi: 10.1111/j.1440-1746.2009.06132.x. Epub 2010 Jan 14. Review.

PMID:
20074149
17.

Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes.

Rodriguez E, Henrique Pereira G, Solà E, Elia C, Barreto R, Pose E, Colmenero J, Fernandez J, Navasa M, Arroyo V, Ginès P.

Liver Transpl. 2015 Nov;21(11):1347-54. doi: 10.1002/lt.24210.

18.

Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis.

Rodríguez E, Elia C, Solà E, Barreto R, Graupera I, Andrealli A, Pereira G, Poca M, Sánchez J, Guevara M, Soriano G, Alessandria C, Fernández J, Arroyo V, Ginès P.

J Hepatol. 2014 May;60(5):955-61. doi: 10.1016/j.jhep.2013.12.032. Epub 2014 Jan 18. Erratum in: J Hepatol. 2014 Aug;61(2):456.

PMID:
24447876
19.
20.

Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico.

Muñoz LE, Alcalá EG, Cordero P, Martínez MA, Vázquez NY, Galindo S, Mendoza E, Segura JJ.

Ann Hepatol. 2009 Jul-Sep;8(3):207-11.

PMID:
19841499

Supplemental Content

Support Center